Author

S. J. Morse

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:multiome· 1 Organism:non-human primate· 1

Frequent Co-Authors

H. Sugimoto· 2 shared K. A. Arian· 2 shared K. K. Mahadevan· 2 shared M. L. Kirtley· 2 shared R. Kalluri· 2 shared A. M. Lopez· 1 shared A. M. Sockwell· 1 shared A. Maitra· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

H. Sugimoto

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity

X. Luo, K. M. McAndrews, K. A. Arian, S. J. Morse, V. Boeker, S. V. Kumbhar, Y. Hu, K. K. Mahadevan, K. A. Church, S. Chitta, N. T. Ryujin, J. Hensel, J. Dai, D. P. Dowlatshahi, H. Sugimoto, , R. Kalluri

This paper develops an engineered extracellular vesicles-based vaccine platform for combined mRNA and protein delivery, showing tumor regression and immune responses in preclinical models.

bioRxiv · Mar 14, 2024Immunology

Oncogenic KrasG12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8+ T cells dependent manner

K. K. Mahadevan, K. McAndrews, V. LeBleu, S. Yang, H. Lyu, B. Li, A. M. Sockwell, M. L. Kirtley, S. J. Morse, B. M. Moreno Diaz, M. P. Kim, N. Feng, A. M. Lopez, P. A. Guerrero, H. Sugimoto, , R. Kalluri

This study shows that MRTX1133, a KrasG12D inhibitor, reduces early pancreatic lesions and, when combined with immunotherapy, regresses advanced PDAC by enhancing CD8+ T cell activity.

bioRxiv · Feb 15, 2023 · PreprintCancer Biology